Medically reviewed by Jamin Brahmbhatt, MD Key Takeaways Complement 3 glomerulopathy (C3G) is diagnosed with a combination of ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported interim data from Part 1 of an ongoing phase 1/2 trial of ARO-C3 in healthy people as a potential therapy for complement mediated diseases. The ...

Medically reviewed by David Hampton, MD C3G is caused by immune system dysfunction that can lead to kidney issues.When the kidneys don't work as they should, people can experience blood or protein in ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Medical University of South Carolina scientists have uncovered a link between the innate immune system and cognitive problems ...

Some of the greatest advancements in modern medicine started with a scientist taking a risk to boldly pursue new areas of research. For scientists at Alexion — a leading biotech company dedicated to ...

Two new studies presented at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Orlando shed light on how hereditary angioedema (HAE)—a rare, potentially ...

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...